US biopharma Chimerix (Nasdaq: CMRX) has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) for the delivery of up to 1.7 million treatment courses of tablet and suspension formulations of Tembexa (brincidofovir) to the US government.
"A second therapeutic option to ensure the federal government’s readiness for a potential smallpox emergency"
Tembexa is an oral antiviral approved last year by the US Food and Drug Administration in tablet and oral suspension formulations for the treatment of smallpox disease in adult and pediatric patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze